Infant Bacterial Therapeutics AB

Update in progress

IBT-B.ST (Stockholm)

Infant Bacterial Therapeutics AB (publ) is a clinical‑stage pharmaceutical company focused on preventing serious neonatal diseases in premature infants in Sweden. Its lead candidate, IBP‑9414, has completed Phase III trials to prevent necrotizing enterocolitis and improve feeding tolerance. IBP‑1016 targets gastroschisis, while IBP‑1118 aims to prevent retinopathy of prematurity and IBP‑1122 targets vancomycin‑resistant enterococci. Founded 2011, based in Stockholm.